 Neoadjuvant Therapy
"Neoadjuvant Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.
| Descriptor ID |
D020360
|
| MeSH Number(s) |
E02.186.450
|
| Concept/Terms |
Neoadjuvant Therapy- Neoadjuvant Therapy
- Neoadjuvant Therapies
- Therapies, Neoadjuvant
- Therapy, Neoadjuvant
- Neoadjuvant Treatment
- Neoadjuvant Treatments
- Treatment, Neoadjuvant
- Treatments, Neoadjuvant
|
Below are MeSH descriptors whose meaning is more general than "Neoadjuvant Therapy".
Below are MeSH descriptors whose meaning is more specific than "Neoadjuvant Therapy".
This graph shows the total number of publications written about "Neoadjuvant Therapy" by people in this website by year, and whether "Neoadjuvant Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 | | 2001 | 1 | 1 | 2 | | 2002 | 0 | 2 | 2 | | 2003 | 0 | 1 | 1 | | 2004 | 2 | 0 | 2 | | 2005 | 3 | 1 | 4 | | 2006 | 1 | 4 | 5 | | 2007 | 1 | 3 | 4 | | 2008 | 3 | 3 | 6 | | 2009 | 1 | 0 | 1 | | 2010 | 1 | 5 | 6 | | 2011 | 3 | 3 | 6 | | 2012 | 5 | 4 | 9 | | 2013 | 2 | 5 | 7 | | 2014 | 4 | 4 | 8 | | 2015 | 2 | 3 | 5 | | 2016 | 3 | 14 | 17 | | 2017 | 4 | 13 | 17 | | 2018 | 6 | 9 | 15 | | 2019 | 9 | 14 | 23 | | 2020 | 13 | 14 | 27 | | 2021 | 8 | 20 | 28 | | 2022 | 7 | 13 | 20 | | 2023 | 5 | 19 | 24 | | 2024 | 11 | 18 | 29 | | 2025 | 5 | 13 | 18 | | 2026 | 4 | 5 | 9 |
To return to the timeline, click here.
Below are the most recent publications written about "Neoadjuvant Therapy" by people in Profiles.
-
Galsky MD, Valderrama BP, Maruzzo M, Font A, Ciuleanu T, Chatzkel J, Koie T, Hoimes CJ, Puente J, Zakharia Y, Rosenbaum E, Boehm K, Loriot Y, Bedke J, Powles TB, Necchi A, Wiechno P, Álvarez-Fernández C, Kim TH, Oliveira N, Flaig TW, Wirtz HS, Mihm M, Huang Q, Rogiers A, Homet Moreno B, Gómez de Liaño A. Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer. N Engl J Med. 2026 Jul 23; 395(4):338-348.
-
Poletto E, Olthof PB, Ruzzenente A, Adam JP, Alwayn IPJ, Boleslawski E, de Boer MT, Chebaro A, Chiche L, Dopazo C, Dubbeld J, Erdmann JI, Hakeem A, Coenraad MJ, Kuipers H, Mabrut JY, Maulat C, Maithel SK, de Meijer VE, Mohkam K, Murad SD, Muscari F, Rolinger J, Polak WG, Rayar M, Ratti F, Robin F, Schnitzbauer AA, Sparrelid E, Van Vilsteren FGI, Porte RJ, Hoogwater FJH, Groot Koerkamp B. Outcomes of Liver Transplant Versus Partial Hepatectomy for Perihilar Cholangiocarcinoma Patients Requiring Arterial Reconstruction. Liver Int. 2026 Jul; 46(7):e70729.
-
Wong EYT, Damle SR, Shiu KK, Cohen SA, Lieu CH. Immunotherapy in Localized Colorectal Cancer: Current Practice and Future Directions. Am Soc Clin Oncol Educ Book. 2026 Jun; 46(3):e520600.
-
Molnár A, Rodriguez Franco S, Sugawara T, Croce C, Kirsch MJ, Svensson J, Stoop TF, Messersmith WA, Schulick RD, Franklin O, Del Chiaro M. Neoadjuvant multiagent chemotherapy or upfront surgery for primary resectable pancreatic cancer - A retrospective intention-to-treat analysis. HPB (Oxford). 2026 Jul; 28(7):932-944.
-
Wach MM, Bank H, Kelly K, Le T, Derby J, Nunns G, Zureikat AH, Bartlett DL, Ahrendt SA, Pingpank JF, Choudry HA, Ongchin M. A Retrospective Examination of Neoadjuvant Chemotherapy for Metachronous Colorectal Peritoneal Metastases Prior to CRS/HIPEC. Ann Surg Oncol. 2026 Jul; 33(7):6175-6184.
-
Herb J, Bassett RL, Torres-Cabala CA, Prieto VG, Patel SP, Holder AM, Fisher SB, Lucci A, Wargo J, Amaria RN, Davies MA, Glitza Oliva IC, Tawbi HA, McQuade J, Ikeguchi AP, Wong MK, Diab AK, Gershenwald JE, Ross MI, Weiser R. Real-World Outcomes for Patients with Clinically Node-Positive Melanoma Undergoing Neoadjuvant Immunotherapy and Nodal Dissection. Ann Surg Oncol. 2026 Jul; 33(7):6700-6708.
-
Haw Y, Krings G, Hsiao WY, Zhan H, Hou Y, Zhang G, Zhang H, Wei S, Yang W, Laé M, Post MD, Liu Y, Shamir ER, Rosa M, Siziopikou K, Schnitt S, Chen YY, Li X. Clinicopathologic Analyses of 34 Cases of High-Grade Serous-Like Carcinoma (HG-SL-Ca) of the Breast. Am J Surg Pathol. 2026 May 01; 50(5):543-549.
-
Kendra KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, Campbell KM, Carson WE, Wada DA, Plaza JA, In GK, Ikeguchi A, Hyngstrom J, Brohl AS, Chmielowski B, Khushalani NI, Markowitz J, Monroe M, Contreras CM, Bowles T, Norman K, Medina E, Gonzalez CR, Baselga-Carretero I, Garcilazo IP, Vega-Crespo A, Chen JM, Deen NNA, Patel SP, Grossmann KF, Sondak VK, Sharon E, Moon J, Wu MC, Ribas A. Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial. Nat Cancer. 2026 Feb; 7(2):272-282.
-
Kong T, Mabry A, Highkin M, Wang AZ, Hoog J, Guo Z, Gonzales-Gonzales A, Thomas S, Song Y, Gao F, Opyrchal M, Peterson L, Ademuyiwa F, Margenthaler J, Aft R, Glover-Collins K, Nehring L, Tao Y, Sanati S, Hagemann IS, Boulos F, Holt M, Ding L, Zhu W, Oh ST, Wang J, Witkiewicz AK, Knudsen ES, Bose R, Weber JD, Goetz M, Northfelt D, Luo J, Ma CX. Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial. Nat Commun. 2026 Jan 27; 17(1):949.
-
Boysen M, Lai SH, Byers S, Widmar M, Loria A, Russell T, Abelson JS, Fleming FJ, Monson JR, Vogel JD. Rectal Cancer Watch-and-Wait Management of Patients With Tumors Within Versus Beyond the Reach of Digital Rectal Examination. Ann Surg Oncol. 2026 Apr; 33(4):2856-2864.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|